Danish pharmaceutical company Novo Nordisk (NVO, Financial) saw its shares drop by 19.17% to $83.61 in pre-market trading. This decline follows the release of trial data for its new weight loss drug, CagriSema. The drug demonstrated a significant weight reduction of 22.7% in patients, but this result fell short of previous expectations.
Meanwhile, Eli Lilly experienced a 7% increase in its pre-market stock price. The contrasting movements in the stock prices of these companies highlight the market's reaction to the latest developments in the weight loss drug sector.
